Jazz Pharma Target RAISED and 4 Stock Analyses Making Waves

Walt Disney Co. (NYSE:DIS): Following a federal judge’s denial of an injunction request made by large broadcasters against a start-up delivering broadcast TV content. According to Wells Fargo, the judge wrote that plaintiffs do not show a high probability of succeeding in a full trial. However, the firm does not see this start-up as an important threat to the TV industry because it does not view the product as compelling. The firm also does not view the start-up as a real threat to retransmission fees.

Align Technology Inc. (NASDAQ:ALGN): According to Credit Suisse’s checks, Q2 dental activity shows a small uptick, but because of the 17% year-to-date group performance, the firm views the expectations as too high headed into earnings. The firm reduced estimated due to lowered consumer sentiment as well as the macro economic outlook.

Don’t Miss: Will Apple DODGE Earnings Skeptics With A SURPRISE?

Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) price target was increased by Lazard Capital, who thinks near-term generic competition for Xyrem has been priced into the company’s shares at current levels. The firm predicts that the Azur merger along with the acquisition of EUSA will generate long-term benefits, and maintains its Buy rating on the shares.

Coach Inc. (NYSE:COH) price target was reduced by Credit Suisse due to lowered retail prices, but the firm states that this is a Buying opportunity because of the recent weakness. The shares have an Outperform rating.

Don’t Miss: These 4 Blue-Chips are NOT FOLDING after Jobless Report.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.